H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Hold rating due to a combination of factors surrounding Shattuck Labs’ current position and future prospects. The upcoming Phase 1 readout for SL-325, expected in the second quarter of 2026, is seen as a crucial event that could potentially reduce risk for the company. This readout will provide important insights into the drug’s mechanism and its applicability from healthy volunteers to patients, which is vital for its development as a treatment for inflammatory bowel disease.
Additionally, Shattuck Labs’ strong financial standing, with sufficient cash to support operations through at least one Phase 2 study, minimizes the immediate risk of dilution. While the company’s pipeline expansion into bispecific antibodies presents potential future opportunities, the current focus remains on advancing SL-325. The financial results for the third quarter of 2025 showed a narrower loss than expected, and the company maintains a solid cash position, which should sustain its operations into 2029. These elements collectively justify the Hold rating, as the company is positioned for potential growth but faces significant milestones that need to be achieved.
According to TipRanks, Pantginis is a 3-star analyst with an average return of 2.2% and a 44.09% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Celldex, Kura Oncology, and Iovance Biotherapeutics.